Egualia on Trump and generic drugs: "Security supply comes before commercial barriers"
22 July 2026 in Milan, 22 Jul. - "The today's statements of American President Donald Trump represent a change of scenario that deserves the..
- Center-right1
- Agency2
2 agency rewrites / co-publications detected
Summary
It is the fear of Riccardo Zagaria, president of Egualia, the association of companies producing equivalent drugs, biosimilar and Value Added Medicines, who comments in a note the intention of the US Administration to introduce duties on generic medicines since 2028. The introduction of trade barriers on products representing more than 90% of the prescriptions in the United States is also likely to aggravate the tensions already existing in supply chains of essential medicines.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
It is the fear of Riccardo Zagaria, president of Egualia, the association of companies producing equivalent drugs, biosimilar and Value Added Medicines, who comments in a note the intention of the US Administration to introduce duties on generic medicines since 2028.
according to Il TempoThe introduction of trade barriers on products representing more than 90% of the prescriptions in the United States is also likely to aggravate the tensions already existing in supply chains of essential medicines.
according to Il Tempo
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Center-right1
Agency1
